In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.
In 2018 the United States invested $371 million in tuberculosis research and development (R&D). South Africa invested $4.5 million (R64,9 million) – a dramatic decrease on 2017, but still high when measured as a proportion of all R&D spending in the country.